WASHINGTON - Reauthorization of the Prescription Drug User Fee Act and FDA reform legislation (S. 830) will be near the top of a very full agenda when the Senate resumes its work this week. But the Senators will be asked to vote on a revised version of S. 830 that many of them still have not seen, and the prospect of last-minute roadblocks erected by Sen. Edward Kennedy continues to haunt efforts to link reform provisions with PDUFA, which exipires at the end of the month.

The current version of S. 830 reflects negotiations between Republicans on the Labor and Human Resources Committee and Kennedy (D-Mass.), as well as the Clinton administration, that took place in the final days before the August recess.